Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 4/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 3/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986262 | 0.94 | UGT2B7 (0.40) | UGT2B7EPHX1MEN1ALDH1A1MAPT | |
| SCHEMBL3987464 | 0.81 | UGT2B7 (0.54) | UGT2B7CDC25ACDC25BMEN1ALDH1A1 | |
| SCHEMBL30933029 | 0.76 | UGT2B7 (0.39) | UGT2B7CDC25AMEN1ALDH1A1MAPT | |
| SCHEMBL3983378 | 0.76 | UGT2B7 (0.34) | UGT2B7CDC25AMEN1ALDH1A1MAPT | |
| SCHEMBL3384132 | 0.75 | UGT2B7 (0.53) | UGT2B7CDC25AMEN1ALDH1A1MAPT | |
| SCHEMBL31250277 | 0.75 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL3988738 | 0.75 | EPHX1 (0.42) | UGT2B7EPHX1 | |
| SCHEMBL25177666 | 0.72 | KDM4E (0.33) | MAPTKMT2A | |
| SCHEMBL3984188 | 0.72 | ALDH1A1 (0.43) | UGT2B7MEN1ALDH1A1KMT2A | |
| SCHEMBL3984235 | 0.71 | MEN1 (0.37) | UGT2B7MEN1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | claimed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | claimed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | claimed |
| EP-4436974-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023097230-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | UGT2B7 1481/4885EPHX1 1196/4885CDC25A 2067/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | UGT2B7 1481/4885EPHX1 1196/4885CDC25A 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.